Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...

Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model to carry out vital cancer research, offering new insights into potential therapies for the ...

In a world-first human trial, Australian researchers have achieved a major milestone in heart disease prevention with a new ...

Researchers say the breakthrough is an important step forward in being able to carry out medical research without the use of animals.

Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, HHS leaders said while announcing new draft guidance.

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 ...

Scientists have discovered a groundbreaking technology that is showing remarkable success in significantly reducing bad ...

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...